Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Article Title: A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way
doi: 10.1093/cid/ciw474
Figure Lengend Snippet: Effect of a new faropenem, linezolid, and moxifloxacin (FLM) regimen over 1 month. A , Kill slopes of the different regimens based on a linear regression model and 95% confidence bounds. The r 2 for the FLM regimen was 0.92, for high-dose moxifloxacin (FLM Hi ) was 0.84, for FLM Hi with ethambutol (EMB) was 0.84, and for standard therapy was 0.73. B , Exponential decline model. The decline rates of all the regimens were similar to standard therapy. C , Time to positivity (TTP) of contents from each hollow fiber system shows that there is no sterilization up to day 28 with TTP when compared to Mycobacterium tuberculosis ( Mtb ) log colony-forming units (CFU)/mL, which revealed sterilization. In this experiment we started with a higher bacterial burden, an acid test. Results of multiple t test comparison shown as * P value of .045 on day 7 and ** P = .011 for day 21. However, by day 28 the TTPs were similar in all drug treatment regimens.
Article Snippet: Faropenem sodium hydrate powder was purchased from BOC Sciences (Shirley, New York).
Techniques: Comparison